Therefore, anti-CD7 and anti-CCR8 dual CAR T cells may be a good choice to prevent antigen escape and further improve the antitumor effect of CCR8+ T-ALL treatment. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.